Danaher Corporation · NYSE:DHR
Danaher — Q2 2020 Earnings Presentation
16 slides from Danaher's earnings presentation, Jul 23, 2020
Slide 1: Danaher Corporation Second Quarter 2020 Earnings Release
DANAHER CORPORATION Second Quarter 2020 Earnings Release July 23, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated financial performance for the third quarter 2020 or any other future period, and any other statements regarding events or developments that we anticip
Slide 3: Second Quarter 2020 Performance Summary: Adjusted Diluted Net Earnings Per Share
Second Quarter 2020 Performance Summary ADJUSTED DILUTED NET EARNINGS PER COMMON SHARE +19.0% +32.0% Core incl. Cytiva +3.5% FX -2.0% ($ millions) Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions,” “Core,” “Core incl. Cytiva,” and “FX,” please r
Slide 4: Second Quarter 2020 Performance Summary: Margins
Second Quarter 2020 Performance Summary GROSS MARGINS Q2 2020 – 53.8% -240 BPS Q2 2019 – 55.9% -210 BPS Core -80 bps Acquisitions +240 bps Other -400 bps SG&A (as a % of Revenue) Q2 2020 – 31.8% Q2 2019 – 31.3% +50 BPS R&D (as a % of Revenue) Q2 2020 – 6.1% Q2 2019 – 6.3% -20 BPS Throughout this pre
Slide 5: Second Quarter 2020 Performance Summary: Free Cash Flow
Second Quarter 2020 Performance Summary FREE CASH FLOW PERFORMANCE ($ millions) +41.0% +33.5% For the definition of Free Cash Flow, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website. 5
Slide 6: Second Quarter 2020: Life Sciences
Second Quarter 2020: Life Sciences +54.5% -450 BPS Core incl. Cytiva +8.0% Core +30 bps FX -1.0% Acquisitions +385 bps Other -865 bps ($ millions) 6
Slide 7: Second Quarter 2020: Diagnostics
Second Quarter 2020: Diagnostics +2.5% +20 BPS Core +5.0% Core +20 bps Acquisitions —% Acquisitions — bps FX -2.5% Other — bps ($ millions) 7
Slide 8: Second Quarter 2020: Environmental & Applied Solutions
Second Quarter 2020: Environmental & Applied Solutions -10.5% -110 bps Core -8.5% Core -110 bps Acquisitions —% Acquisitions — bps FX -2.0% Other — bps ($ millions) 8
Slide 9: Guidance
GUIDANCE 9
Slide 10: Q&A
Q&A OD wana
Slide 11: Danaher
DANAHER
Slide 12: Non-GAAP Reconciliations
Non-GAAP Reconciliations Core Sales Growth and Core Sales Growth Including Cytiva Year-Over-Year Core Operating Margin Changes From Continuing Operations % Change Three-Month Period Ended July 3, 2020 Segments vs. Comparable 2019 Period Environmental Total Company Life Sciences Total Life & Applied
Slide 13: Non-GAAP Reconciliations
Non-GAAP Reconciliations Reconciliation of Operating Cash Flows from Continuing Operations (GAAP) to Free Cash Flow from Continuing Operations (Non-GAAP) Three-Month Period Ended Three-Month Period Ended Six-Month Period Ended April 3, March 29, July 3, June 28, Year-over- July 3, June 28, Year-over
Slide 14: Non-GAAP Reconciliations: Notes
Non-GAAP Reconciliations A Notes to Reconciliation of GAAP to Non-GAAP Financial Measures Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above): Adjusted Di
Slide 15: Statement Regarding Non-GAAP Measures
Statement Regarding Non-GAAP Measures Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes t
Slide 16: Danaher
DANAHER